ArticleFrontiers in medicine2026
Prospective longitudinal study of psychological sequelae, self-perception of body image, and quality of life in severe cutaneous adverse drug reactions: a case-control study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe cutaneous adverse drug reactions (SCARs) are associated with mental health sequelae and reduced quality of life. However, existing research is limited by small retrospective cohorts, overrepresentation of high-income countries, lighter skin tones, inadequate controls, and a paucity of prospective longitudinal case-control studies assessing the psychological sequelae in SCAR. Objective: This study aimed to prospectively determine and compare the longitudinal trajectories of psychological sequelae in patients with SCAR and controls. Methods: Between June 2020 and October 2023, SCAR cases and matched controls were recruited. The following validated instruments were used for assessments: (1) the MINI International Neuropsychiatric Interview to assess depression and suicide risk; (2) the Kessler Psychological Distress Scale (K10) to determine pre-existing depression; (3) the Cutaneous Body Image (CBI) scale to measure self-perception of body image; and (4) the Dermatology quality life index (DQLI) to measure the impact of SCAR on health-related quality of life (QoL). Assessments were conducted at admission (baseline or Results: Total of 47 SCAR cases (8 SJS/TEN, 35 DRESS, and 4 GBFDE) and 30 controls were recruited. All had Fitzpatrick skin types ≥III. Cases had significantly higher prevalence of depression [21/47 (45%) vs. 4/30 (13.3'%), Conclusion: SCARs were found to be associated with a high risk of depression, suicide, impaired QoL, and severe negative self-perception compared to controls. SCAR patients demonstrated persistent or worsening impairments at 6 months and relapses at 12 months. These findings highlight the ongoing psychosocial burden of SCARs and the need for integrated mental health support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.